Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 1031-1043
Closed Access | Times Cited: 178

Showing 1-25 of 178 citing articles:

Diagnosis and Treatment of Chronic Lymphocytic Leukemia
Mazyar Shadman
JAMA (2023) Vol. 329, Iss. 11, pp. 918-918
Closed Access | Times Cited: 113
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 33-44
Open Access | Times Cited: 110
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia
B. Eichhorst, Paolo Ghia, Carsten Utoft Niemann, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 762-768
Closed Access | Times Cited: 18
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. 744-759
Open Access | Times Cited: 16
Chronic lymphocytic leukemia treatment algorithm 2022
Paul J. Hampel, Sameer A. Parikh
Blood Cancer Journal (2022) Vol. 12, Iss. 11
Open Access | Times Cited: 44
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1504-1504
Open Access | Times Cited: 33
Zanubrutinib: past, present, and future
Constantine S. Tam, Javier Muñoz, John F. Seymour, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
BTK inhibitors in CLL: second-generation drugs and beyond
Constantine S. Tam, Philip A. Thompson
Blood Advances (2024) Vol. 8, Iss. 9, pp. 2300-2309
Open Access | Times Cited: 14
Chronic lymphocytic leukaemia
Nitin Jain, William G. Wierda, Susan O’Brien
The Lancet (2024) Vol. 404, Iss. 10453, pp. 694-706
Closed Access | Times Cited: 14
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
Samir Mouhssine, Nawar Maher, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3234-3234
Open Access | Times Cited: 12
Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
Amneh A Fares, Carlos Carracedo Uribe, Diana Martinez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2208-2208
Open Access | Times Cited: 11
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Rory Bennett, John F. Seymour
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Matthew S. Davids, Jeff P. Sharman, Paolo Ghia, et al.
Blood Advances (2024) Vol. 8, Iss. 13, pp. 3345-3359
Open Access | Times Cited: 8
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors
Stefano Molica, David Allsup
Cancers (2025) Vol. 17, Iss. 1, pp. 119-119
Open Access | Times Cited: 1
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
John N. Allan, Ian W. Flinn, Tanya Siddiqi, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2593-2601
Open Access | Times Cited: 21
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
Alexandra Chirino, Skye Montoya, Anita Safronenka, et al.
Genes (2023) Vol. 14, Iss. 12, pp. 2182-2182
Open Access | Times Cited: 19
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Rory Bennett, Mary Ann Anderson, John F. Seymour
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 18
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
Othman Al‐Sawaf, Rudy Ligtvoet, Sandra Robrecht, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 240-248
Open Access | Times Cited: 18
The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
Toby A. Eyre, John C. Riches
Cancers (2023) Vol. 15, Iss. 9, pp. 2596-2596
Open Access | Times Cited: 17
CAR-T cell combination therapies in hematologic malignancies
Delian Zhou, Xiaojian Zhu, Yi Xiao
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Prognostication in chronic lymphocytic leukemia
Riccardo Moia, Gianluca Gaïdano
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 83-90
Open Access | Times Cited: 6
BTK inhibitors: past, present, and future
Allison Cool, Tiffany Nong, Skye Montoya, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 8, pp. 691-707
Closed Access | Times Cited: 6
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease
Janina Stumpf, Othman Al‐Sawaf
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 136-146
Open Access | Times Cited: 5
Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints
Stefano Molica
Expert Review of Hematology (2024) Vol. 17, Iss. 7, pp. 279-285
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top